GlassScriptPhysician profile
Cuong D Nguyen
NPI 1659497451
$2,297.97
in general payments reported to CMS, 2019-2025
25 companies · $689 in 2025
The $689 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.02 · 2020: $28.13 · 2021: $42.32 · 2022: $66.01 · 2023: $375 · 2024: $1,002 · 2025: $689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,925 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,925.32 |
| Education | $140.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $487.70 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $444.71 | 2022-2025 | Farxiga, Lokelma |
| Amgen INC. | $208.73 | 2024-2025 | Krystexxa, Tavneos |
| Otsuka America Pharmaceutical, INC. | $203.42 | 2019-2025 | Jynarque |
| Outset Medical INC | $117.26 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $111.30 | 2022-2025 | |
| Ardelyx, INC. | $81.23 | 2024-2025 | Ibsrela |
| Glaxosmithkline, LLC. | $74.16 | 2021-2025 | Benlysta |
| Horizon Therapeutics Plc | $72.29 | 2019-2023 | Krystexxa |
| Akebia Therapeutics INC | $58.98 | 2019-2025 | Vafseo |
| Calliditas Therapeutics US INC. | $47.74 | 2025 | Tarpeyo |
| Pharmacosmos Therapeutics INC. | $45.33 | 2025 | Monoferric |
| Novo Nordisk INC | $42.27 | 2024 | Rivfloza |
| Shield Therapeutics INC | $41.67 | 2025 | |
| Mallinckrodt Hospital Products INC. | $33.63 | 2025 | Terlivaz |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $30.29 | 2025 | Empaveli |
| Vifor Pharma, INC. | $28.13 | 2020 | |
| Lilly USA, LLC | $27.75 | 2024 | Jardiance |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $27.53 | 2024 | |
| Novartis Pharmaceuticals Corporation | $24.72 | 2025 | |
| Daiichi Sankyo INC. | $22.94 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.55 | 2025 | Jardiance |
| Opko Pharmaceuticals, LLC | $18.20 | 2022 | |
| Scpharmaceuticals INC. | $14.37 | 2025 | |
| Amag Pharmaceuticals, INC. | $13.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cuong Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.